Key Highlights

  • Nurix Therapeutics (NASDAQ:NRIX) slid 28.16% to USD 18.55 after Sanofi disclosed it will halt an oral STAT6 degrader trial.
  • Dyne Therapeutics (NASDAQ:DYN) dropped 8.98% to USD 16.43 with no new announcement identified, ahead of a January 21, 2027 FDA date.
  • Spyre Therapeutics (NASDAQ:SYRE) fell 8.71% to USD 90.62 following a USD 96.1 million quarterly loss.
  • RxSight (NASDAQ:RXST) declined 9.59% to USD 4.15 after third quarter Revenue dropped 19% to USD 24.6 million.
  • Nuwellis (NASDAQ:NUWE) lost 11.34% to USD 5.24 with no confirmed catalyst following a reverse split.

Nurix Therapeutics (NASDAQ:NRIX) (down USD 7.27, 28.16%): Sanofi Brings the STAT6 Degrader Work to a Close

Nurix Therapeutics (NASDAQ:NRIX) traded at USD 18.55 in pre-market trading on November 4, 2026, down 28.16% or USD 7.27 from the Tuesday, November 3, 2026 close. That points to a prior close of about USD 25.82 (calculated). The likely trigger is a company release issued at 4:01 p.m. ET on November 3, 2026, stating that Sanofi had informed the company it will stop the Phase 1 trial of SAR448272, an oral STAT6 degrader.

The release offered no reason. The company does not expect milestones or royalties from that program, although it stays eligible on other licensed programs, and it said cash runway guidance is unchanged. Cash stood at USD 1.1 billion on August 31, 2026. The main risk is reliance on partners, since the company still depends on Roche for bexobrutideg.

Dyne Therapeutics (NASDAQ:DYN) (down USD 1.62, 8.98%): A Gradual Slide Ahead of a January FDA Date

Dyne Therapeutics (NASDAQ:DYN) changed hands at USD 16.43 in pre-market trading on November 4, 2026, implying a prior close near USD 18.05, calculated from the screen data. No press release or filing dated November 2 to November 4, 2026 turned up, so the decline looks driven by sentiment.

The backdrop is z-rostudirsen for exon 51 Duchenne muscular dystrophy, with a Priority Review target action date of January 21, 2027. The net loss for the second quarter of 2026 widened to USD 178.6 million from USD 110.9 million, and cash was USD 898.5 million at June 30, 2026, before a July offering of about USD 431 million gross. Key risks are the regulatory outcome, rising launch costs and dilution.

Spyre Therapeutics (NASDAQ:SYRE) (down USD 8.65, 8.71%): A Bigger Loss Alongside Positive Phase 2 Readouts

Spyre Therapeutics (NASDAQ:SYRE) was off 8.71% at USD 90.62 in pre-market trading on November 4, 2026, from an implied prior close of about USD 99.27 (calculated). The decline follows third quarter results released on November 3, 2026, although no single cause has been confirmed.

The net loss came in at USD 96.1 million compared with USD 11.2 million a year earlier. The company also reported that all three monotherapies in Part A of its ulcerative colitis study met their primary endpoints, while two SPY072 rheumatic studies missed theirs. Pro forma cash was USD 1,467.9 million including October financing. The risks are trial, regulatory and dilution exposure, with Part B induction data expected in the third quarter of 2027.

RxSight (NASDAQ:RXST) (down USD 0.4402, 9.59%): Sales Decline Weighs on a Penny Stock

RxSight (NASDAQ:RXST) traded at USD 4.15 in pre-market trading on November 4, 2026, down 9.59% from an implied prior close of about USD 4.59 (calculated). The move followed third quarter results released after the regular session on November 3, 2026.

Revenue fell 19% to USD 24.6 million, Light Adjustable Lens Volume dropped 11% to 23,128 units, gross Margin slipped to 73.6% from 79.9%, and net loss reached USD 16.2 million. Management pointed to seasonality, competition and sales force disruption. As a Penny Stock trading below USD 5, the shares can be highly volatile, with limited Liquidity and possible Equity raises.

Nuwellis (NASDAQ:NUWE) (down USD 0.6702, 11.34%): Handing Back Gains After the Reverse Split

Nuwellis (NASDAQ:NUWE) fell 11.34% to USD 5.24 in pre-market trading on November 4, 2026, from a USD 5.91 close on November 3. No company announcement dated November 3 or November 4, 2026 turned up, so the decline is not tied to a confirmed catalyst. A plausible backdrop is profit taking after a sharp run that followed the Reverse Stock Split disclosed on October 23, 2026.

Second quarter 2026 revenue was USD 1.97 million, up about 14%, with gross margin of 76% and a net loss of about USD 4.8 million. The main risk is Going Concern and Nasdaq compliance language, with further Capital raising possible. The shares are volatile and thinly traded.

Where Things Stand

These five stocks slid for different reasons: a partner ending a program at Nurix (NASDAQ:NRIX), results at Spyre (NASDAQ:SYRE) and RxSight (NASDAQ:RXST), and no identified announcement at Dyne (NASDAQ:DYN) and Nuwellis (NASDAQ:NUWE). Watch the January 21, 2027 FDA date at Dyne, any explanation for the Sanofi decision at Nurix, fourth quarter lens volume at RxSight, the Nuwellis third quarter report, and the Spyre Part B readout.